Adrian Kilcoyne - Nov 23, 2021 Form 4 Insider Report for HUMANIGEN, INC (HGEN)

Role: Chief Medical Officer
Signature: /s/ Timothy Morris, Attorney-in-Fact
Stock symbol: HGEN
Transactions as of: Nov 23, 2021
Transactions value $: -$26,559
Form type: 4
Date filed: 11/26/2021, 04:15 PM
Previous filing: Oct 4, 2021
Next filing: Jan 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HGEN	Stock Option (Right to Buy)	Disposed to Issuer	-$26.6K	-5.86K	-100%	$4.53	0	Nov 23, 2021	Common Stock	5.86K	$5.93	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	As reported in a Form 8-K filed by Humanigen, Inc. (the "Company") on November 26, 2021, with the approval of the compensation committee of the board of directors of the Company, the reporting person accepted the Company's offer to rescind his participation in the program pursuant to which the reporting person had agreed to receive stock options in lieu of 25% of his base salary for the fourth quarter of 2021, or $26,546. As a result, the stock option granted to the reporting person on September 30, 2021 was cancelled, and the reporting person will receive 100% of his base salary for the fourth quarter of 2021 in cash. The amount shown in column 8 equals the fair value of the option on the grant date of September 30, 2021 as calculated using the Black-Scholes options pricing model.

Content

As reported in a Form 8-K filed by Humanigen, Inc. (the "Company") on November 26, 2021, with the approval of the compensation committee of the board of directors of the Company, the reporting person accepted the Company's offer to rescind his participation in the program pursuant to which the reporting person had agreed to receive stock options in lieu of 25% of his base salary for the fourth quarter of 2021, or $26,546. As a result, the stock option granted to the reporting person on September 30, 2021 was cancelled, and the reporting person will receive 100% of his base salary for the fourth quarter of 2021 in cash. The amount shown in column 8 equals the fair value of the option on the grant date of September 30, 2021 as calculated using the Black-Scholes options pricing model.